FTRE Quote, Financials, Valuation and Earnings

Cytokinetics, Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of -15814.98%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Cytokinetics, Inc.'s return on equity of --.

Fortrea Holdings, Inc. has a consensus price target of $16.44, signalling upside risk potential of 49.42%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $90.39 which suggests that it could grow by 33.04%. Given that Fortrea Holdings, Inc. has higher upside potential than Cytokinetics, Inc., analysts believe Fortrea Holdings, Inc. is more attractive than Cytokinetics, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.536, suggesting its less volatile than the S&P 500 by 46.407%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are larger than Cytokinetics, Inc. quarterly revenues of $1.9M. Fortrea Holdings, Inc.'s net income of -$15.9M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.36x versus 92.71x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Humana, Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of -2.39%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Humana, Inc.'s return on equity of 6.77%.

Fortrea Holdings, Inc. has a consensus price target of $16.44, signalling upside risk potential of 49.42%. On the other hand Humana, Inc. has an analysts' consensus of $226.75 which suggests that it could grow by 19.45%. Given that Fortrea Holdings, Inc. has higher upside potential than Humana, Inc., analysts believe Fortrea Holdings, Inc. is more attractive than Humana, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.287%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana, Inc. offers a yield of 1.87% to investors and pays a quarterly dividend of $0.89 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Humana, Inc. pays out 36% of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are smaller than Humana, Inc. quarterly revenues of $32.5B. Fortrea Holdings, Inc.'s net income of -$15.9M is higher than Humana, Inc.'s net income of -$776M. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Humana, Inc.'s PE ratio is 19.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.36x versus 0.18x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Medpace Holdings, Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of 19.08%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Medpace Holdings, Inc.'s return on equity of 96.22%.

Fortrea Holdings, Inc. has a consensus price target of $16.44, signalling upside risk potential of 49.42%. On the other hand Medpace Holdings, Inc. has an analysts' consensus of $486.92 which suggests that it could grow by 7.31%. Given that Fortrea Holdings, Inc. has higher upside potential than Medpace Holdings, Inc., analysts believe Fortrea Holdings, Inc. is more attractive than Medpace Holdings, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Medpace Holdings, Inc. has a beta of 1.422, suggesting its more volatile than the S&P 500 by 42.175%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medpace Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Medpace Holdings, Inc. pays out -- of its earnings as a dividend.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are smaller than Medpace Holdings, Inc. quarterly revenues of $708.5M. Fortrea Holdings, Inc.'s net income of -$15.9M is lower than Medpace Holdings, Inc.'s net income of $135.1M. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Medpace Holdings, Inc.'s PE ratio is 29.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.36x versus 5.30x for Medpace Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare, Inc. has a net margin of -2.27% compared to Fortrea Holdings, Inc.'s net margin of -1.41%. Fortrea Holdings, Inc.'s return on equity of -104.76% beat Molina Healthcare, Inc.'s return on equity of 10.89%.

Fortrea Holdings, Inc. has a consensus price target of $16.44, signalling upside risk potential of 49.42%. On the other hand Molina Healthcare, Inc. has an analysts' consensus of $157.56 which suggests that it could grow by 4.35%. Given that Fortrea Holdings, Inc. has higher upside potential than Molina Healthcare, Inc., analysts believe Fortrea Holdings, Inc. is more attractive than Molina Healthcare, Inc..

Fortrea Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Molina Healthcare, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.546%.

Fortrea Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings, Inc. pays -- of its earnings as a dividend. Molina Healthcare, Inc. pays out -- of its earnings as a dividend.

Fortrea Holdings, Inc. quarterly revenues are $701.3M, which are smaller than Molina Healthcare, Inc. quarterly revenues of $11.4B. Fortrea Holdings, Inc.'s net income of -$15.9M is higher than Molina Healthcare, Inc.'s net income of -$160M. Notably, Fortrea Holdings, Inc.'s price-to-earnings ratio is -- while Molina Healthcare, Inc.'s PE ratio is 17.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings, Inc. is 0.36x versus 0.18x for Molina Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.